Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/613668


Zimbabwe Pharmaceuticals and Healthcare Report Q2 2008


Description: The Zimbabwe Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Zimbabwes pharmaceuticals and healthcare industry.

Zimbabwe’s pharmaceutical sector continues to struggle under the weight of international sanctions and hyperinflation. We estimate the market to have been worth US$4.5mn in 2007 - down 9% on its 2006 value. Despite uncertainties surrounding the economic climate making long term drug market forecasts problematic, we expect the market to shrink further to US$3.7mn by 2012, taking into account thenegative real GDP growth widely expected for the economy as a whole.

A shortage of foreign currency placed severe limits on the ability of pharmacies to import drugs during the second half of 2007. According to reports in the local media, around half of drugs were out of stock in pharmacies surveyed, while those that were available had risen to prices that were multiples of local workers’ salaries.

Meanwhile, Zimbabwe’s manufacturing industry is suffering from similar constraints - with a lack of foreign currency reducing the volume of raw materials that can be imported. Problems at home have made exports a vital source of income and foreign currency. In this regard, CAPS Holdings continues to lead the way with exports to South Africa, Mozambique and Botswana. Meanwhile, Varichem Labs found another source of foreign currency - the UN Development Programme (UNDP) - which supported a US$2.1mn upgrade of its antiretroviral (ARV) manufacturing plant completed in January 2008 that is expected to ensure World Health Organisation (WHO) compliance.

In BMI’s updated business environment ratings for the Middle East and Africa, Zimbabwe scored 15 out of a possible 100 putting it in last place out of 14 markets surveyed. Its poor showing takes into account factors including a small, contracting market, unfavourable regulatory environment and challenging economic and political situation.

Fees in the healthcare sector have struggled to keep pace with inflation. Insurance in particular has suffered because premiums and benefits levels set in advance have been eroded by rises in health fees. Meanwhile, the economic crisis seems to have put pay to any chance of a national health insurance scheme, meaning that out of pocket spending is likely to continue to increase as a proportion of health expenditure.


Contents: Executive Summary
Zimbabwe Pharmaceuticals And Healthcare Industry SWOT
Zimbabwe Political SWOT
Zimbabwe Economic SWOT
Zimbabwe Business Environment SWOT
Pharmaceutical Business Environment Ratings
Regional Pharma Business Environment Ratings
Limits Of Potential Returns
Risks To Realisation Of Returns
Zimbabwe - Market Summary
Regulatory Regime
Intellectual Property Developments
Pricing And Reimbursement Issues
Public Drug Procurement
Industry Developments.
Health Profile
Table: Key Health Indicators
HIV/AIDS Crisis
Recent Regional HIV/AIDS Developments
Healthcare System
Healthcare Funding
Healthcare Staff
Pharmaceutical Sector
Recent Pharmaceutical Sector Developments
Table: ARV Prices Available Through Direct Purchase From Roche (CHF)
Traditional Medicine
Biotechnology Sector Developments
Industry Forecast Scenario
Overall Market Forecasts
Table: Zimbabwe’s Drug Market Forecasts
Key Growth Factors - Industry
Table: Zimbabwe’s Healthcare Expenditure Indicators
Key Growth Factors -Macroeconomic
Table: Zimbabwe - Economic Activity
Prescription Market Forecast
Table: Zimbabwe’s Prescription Drug Market, 2005-2012 (US$mn unless otherwise stated)
OTC Market Forecast
Table: Zimbabwe’s OTC Market, 2005-2012 (US$mn unless otherwise stated)
Generics And Patented Market Forecast
Table: Zimbabwe Generics And Patented Market, 2005-2
Export/Import Forecasts
Table: Zimbabwe’s Import/Domestic Market, 2005-2012
Other Healthcare Data Forecasts
Table: Zimbabwe’s Other Healthcare Forecasts, 2005-2012
Key Risks To BMI Forecasts
Competitive Landscape

Company Profiles

Multinational Companies
- Ranbaxy
- Pfizer
- Novartis
- Sanofi-Aventis
- Merck & Co
- GlaxoSmithKline

Indigenous Companies
- Datlabs
- Varichem Laboratories
- CAPS Holdings

BMI Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources



Companies Mentioned - Ranbaxy - Pfizer - Novartis - Sanofi-Aventis - Merck & Co - GlaxoSmithKline - Datlabs - Varichem Laboratories - CAPS Holdings


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/613668

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 05/09/2008 07:36:43
Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com


Order information

Please verify that the product information is correct and select the format you require.

Product Name:
Zimbabwe Pharmaceuticals and Healthcare Report Q2 2008
Web Address:
http://www.researchandmarkets.com/reports/613668
Office Code:
OCHHGGPNTSS

Report formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €440.00




Contact information

Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World

Research and Markets Page 2 of 2
Printed 05/09/2008 07:36:43

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder Name:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.


If you have a Marketing Code please enter it below:

Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp



Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World